BHCM
ABUS icon

Brevan Howard Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Brevan Howard Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,482
Closed -$27K – 1026
2024
Q1 		$27K Sell
10,482
-7,277
-41% -$18.8K ﹤0.01% 954
2023
Q4 		$44.4K Buy
+17,759
New +$34.8K ﹤0.01% 998

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's ABUS Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2024, closing a stake of 10,482 shares — an estimated $27K sold.

Brevan Howard Capital Management first reported a position in ABUS in Q4 2023 and held it in 2 quarters. The position peaked at $44.4K in Q4 2023. 131 funds tracked by Wall St. Rank hold ABUS as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Arbutus Biopharma position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,482 Arbutus Biopharma shares in Q2 2024, an estimated $27K.
  • Brevan Howard Capital Management first reported a position in Arbutus Biopharma in Q4 2023 and held it in 2 quarters.
  • Brevan Howard Capital Management's Arbutus Biopharma position peaked at $44.4K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.